Ann: Genetic Technologies appoints Mike Tonroe as CFO, page-9

Don't be too amused @TerryJones, the truth may disappoint you...

Keep abreast of the Co's financial position, below from old news released 26th Feb '21:

--> 1H21 Half Year Results

---------
Highlights
• Strong cash balance with pro forma cash balance of A$24.1 million inclusive of capital raiseof US$6.56 million (A$7.69 million) in January 2021
• Early-stage revenue of $16k associated with sale of launched products reflecting a 2700%increase over the previous corresponding period (pcp)
• Received $0.76 million in R&D tax incentives and COVID-19 government assistance
• Partnered with Taliaz for the sale and distribution rights of PREDICTIX
• Expansion of product base into existing reimbursable segments with BRCA and LynchSyndrome
• COVID-19 PRS test is undergoing technical validation with an expanded data set.

Genetic Technologies has made significant inroads over the half on its strategic objectives. TheCompany has further underpinned its future growth following an additional capital raise to ensurethe business can execute on its objectives. Additionally, it is in a strong position with a solid pipelineof products in development and clear opportunities for the sales and distribution of the launchedproducts being GeneType for Breast Cancer and for Colorectal Cancer.
--------

They are making good on their objectives and now have a requirement for an in-house CFO,
maybe the Co is trying to move forward, transitioning maybe..
The above is old news possibly check on Anns when they are released...

GL all.
.